Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Hepatology
•
Hepatology
Do you always consider ADPCKD or ARPCKD in a patient who is incidentally found to have liver and renal cysts?
Related Questions
What is your approach to a patient with an elevated alkaline phosphatase level, but negative PBC serologies and normal biliary imaging?
What is your clinical approach to the evaluation of cytopenias in patients with end-stage liver disease?
How do you approach dosing beta blockers for variceal prophylaxis when the standard dose doesn’t achieve the target heart rate?"
What is your approach to a patient with "low" liver enzymes?
Do you avoid peritoneal dialysis in cirrhotic patients with ascites?
How do you determine whether to limit volume removal during therapeutic paracentesis in a patient without acute or chronic kidney disease?
How do you decide whether ordering a 5' nucleotidase or a GGT is the most appropriate option in the evaluation of an elevated alkaline phosphatase?
How do you utilize Cystatin-C as a marker of renal dysfunction in patients with chronic liver disease?
How do you approach the use of viscoelastic assays (ex: TEG, ROTEM) in patients with identified coagulopathy in the peri-procedural period?
If you do not have easy access to shear wave elastography (aka Fibroscan), what do you recommend for non-invasive tests to determine if a MASLD patient has clinically significant portal hypertension and risk-stratify them?
